Kintegral Advisory LLC Decreases Position in IQVIA Holdings Inc. (NYSE:IQV)

Kintegral Advisory LLC decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,046 shares of the medical research company’s stock after selling 188 shares during the quarter. Kintegral Advisory LLC’s holdings in IQVIA were worth $795,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC purchased a new stake in shares of IQVIA during the fourth quarter worth about $1,616,000. Simplify Asset Management Inc. boosted its stake in IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares in the last quarter. Nordea Investment Management AB grew its position in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. acquired a new position in IQVIA during the 4th quarter valued at approximately $941,000. Finally, Fifth Third Bancorp raised its holdings in shares of IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after buying an additional 1,521 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on IQV shares. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. The Goldman Sachs Group dropped their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Morgan Stanley raised their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Stock Performance

NYSE IQV opened at $190.94 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The stock has a 50-day moving average of $199.57 and a 200 day moving average of $216.34. The stock has a market capitalization of $33.62 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.